Stockscreener 앱 받기
33.92
6.40%
2.04
전일 마감가:
$31.88
열려 있는:
$31.98
하루 거래량:
3.67M
Relative Volume:
1.04
시가총액:
$3.83B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-36.47
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
+6.03%
1개월 성능:
-5.04%
6개월 성능:
+7.24%
1년 성능:
+4.18%
1일 변동 폭
$31.71
$34.28
1주일 범위
$29.54
$36.00
52주 변동 폭
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.92 | 3.60B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Published on: 2026-01-18 12:53:17 - baoquankhu1.vn
Viking Therapeutics Stock (VKTX) Opinions on VK2735 Obesity Drug Results - Quiver Quantitative
Volume Summary: What is AEISs valuation compared to sector2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Viking Therapeutics: A Stock at a Crossroads Amid Obesity Drug Ambitions - AD HOC NEWS
Is Viking Therapeutics (VKTX) Now Attractive After A Strong DCF Upside Signal - Yahoo Finance
Viking Therapeutics Stock Navigates a Week of High Volatility - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
The Escalator: AstraZeneca, Viking Therapeutics, VML Health and more - Medical Marketing and Media
M&A Speculation Fuels Rally in Viking Therapeutics Shares - AD HOC NEWS
Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress - simplywall.st
Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook - Insider Monkey
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Precision Trading with Viking Therapeutics Inc. (VKTX) Risk Zones - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) Trading 8.3% HigherShould You Buy? - MarketBeat
$VKTX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals - TechStock²
Stocks Drop, Energy Sector Rises As Crude Eyes 6th Day Of Gains: What's Moving Markets Wednesday? - Benzinga
SG Americas Securities LLC Acquires 81,519 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Positioning in the Competitive Obesity Drug Arena - AD HOC NEWS
Jim Cramer Says "I'm a Eli Lilly Guy" When Asked About Viking Therapeutics - Finviz
Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics - Insider Monkey
Viking Therapeutics Gains Investor Attention with Key Clinical Data and Strategic Positioning - AD HOC NEWS
Dow Update: Why Viking Therapeutics Inc. stock remains undervaluedMarket Risk Summary & AI Powered Market Entry Ideas - moha.gov.vn
Assessing Viking Therapeutics (VKTX) Valuation After Positive VK2735 Obesity Trial Progress - simplywall.st
Viking Therapeutics Bolstered by Clinical Data and Development Momentum - AD HOC NEWS
Appetite for weight-loss deals broader than visible, Viking CEO says - Reuters
Viking Therapeutics Gains Scientific Endorsement for Weight Loss Candidate - AD HOC NEWS
Profit Recap: Why is Viking Therapeutics Inc stock going upPrice Action & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Viking Therapeutics announces publication of results from Phase 2 VENTURE trial - TipRanks
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity - PR Newswire
Viking Therapeutics Sharpens Commercial Focus for Obesity Drug Pipeline - AD HOC NEWS
What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale - AOL.com
1 bold prediction for Viking Therapeutics in 2026 - MSN
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise - MSN
Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? - Yahoo Finance
Viking Therapeutics: A High-Stakes Bet on Clinical Success - AD HOC NEWS
Viking Therapeutics stock suffers worst day in over 4 months as top execs dump shares — Novo’s $149 Wegovy move looms - MSN
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know - sharewise.com
Why Viking Therapeutics Inc. stock remains on buy listsTrade Volume Summary & Daily Oversold Bounce Ideas - ulpravda.ru
Has The Pullback In Viking Therapeutics (VKTX) Opened A New Valuation Opportunity - simplywall.st
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - Yahoo Finance
Viking Therapeutics Stock Faces Pressure Amid Insider Sales - AD HOC NEWS
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Viking Therapeutics completes enrollment in obesity drug maintenance study By Investing.com - Investing.com Nigeria
Viking Therapeutics completes enrollment in trial of VK2735 - Yahoo Finance
Viking Therapeutics Advances Obesity Drug Development and Commercial Strategy - AD HOC NEWS
Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition? - Sahm
Can Viking Therapeutics Inc. stock maintain growth trajectoryJuly 2025 Snapshot & Real-Time Volume Trigger Notifications - ulpravda.ru
Viking Therapeutics: InvestingPro’s overvalued call proved right amid volatility By Investing.com - Investing.com Nigeria
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Finviz
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
4.73%
0.92%
자본화:
|
볼륨(24시간):